Braster S.A.

Equities

BRA

PLBRSTR00014

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 16:55:55 31/05/2024 BST			5-day change	1st Jan Change
0.58 ^PLN	-.--%		-.--%	-.--%

2023	Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Dom Maklerski Banku Ochrony Srodowiska S.A. sold 5.76% stake in Braster S.A..

July 30, 2016

Dom Maklerski Banku Ochrony Srodowiska S.A. sold 5.76% stake in Braster S.A. (WSE:BRA) on June 30, 2016. Post transaction, Dom Maklerski Banku Ochrony Srodowiska will hold 662 shares in Braster SA. Dom Maklerski Banku Ochrony Srodowiska S.A. completed the sale of 5.76% stake in Braster S.A. (WSE:BRA) on June 30, 2016.

Latest news about Braster S.A.

Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	03/10/23	CI
Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/05/23	CI
Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	03/05/23	CI
Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	03/05/23	CI
Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11/22	CI
Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	27/09/22	CI
Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/05/22	CI
Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	03/05/22	CI
Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	29/11/21	CI
Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	30/09/21	CI
An unknown buyer acquired 21.38% stake in Braster S.A. from Carom Sp. z o.o.	22/09/21	CI
Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	30/04/21	CI
Braster Seeks To Raise Capital	06/07/18	CI
Braster S.A. announced that it has received PLN 0.3 million in funding	10/08/17	CI
Braster S.A. announced that it expects to receive PLN 0.3 million in funding	19/04/17	CI
Braster Negotiates Acquisitions	08/03/17	CI
Braster S.A. announced that it has received funding from Towarzystwo Funduszy Inwestycyjnych PZU SA	06/07/16	CI
Dom Maklerski Banku Ochrony Srodowiska S.A. sold 5.76% stake in Braster S.A..	30/06/16	CI
Medi-Koncept Sp. z o.o. sold 3.15% stake in Braster Spólka Akcyjna.	17/02/15	CI
Tadeusz Wesolowski acquired additional 4.3% stake in Braster Spólka Akcyjna.	16/02/15	CI

Chart Braster S.A.

Duration

Period

More charts

Company Profile

Braster SA w restrukturyzacji, formerly Braster SA, is a Poland-based company principally engaged in the bio diagnostics and testing. The Company provides research and development on breast cancer. It applies liquid crystals and liquid crystal emulsion formula that is used to produce liquid crystal matrix based on LCD technology, continuous film CLCF (Continuous Liquid Crystal Film) in the diagnosis of breast cancer. Its main product is Braster Tester, which is a device that uses thermographic liquid crystal matrices for diagnosing breast cancer; the device is made up of three film matrices covered with a liquid crystal mixture that allows thermal imaging. The Company cooperates with the Jagiellonian University, with the participation of the clinical trial conducted by Thermacrac, among others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
BRASTER S.A.	-.--%	4.32M
EXACT SCIENCES CORPORATION	-38.56%	8.35B
GUARDANT HEALTH, INC.	+0.18%	3.36B
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.52B
BGI GENOMICS CO., LTD.	-18.21%	2.04B
VERACYTE, INC.	-24.57%	1.6B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.18B
SEEGENE, INC.	-7.64%	707M
CAREDX, INC	+8.42%	704M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	532M

Bio Diagnostics & Testing